Syndax's Newly Arrived CEO Briggs Morrison Announces Clinical Collaboration With Genentech
This article was originally published in Scrip
Syndax Pharmaceuticals Inc. - which recently lured respected scientist Briggs Morrison away from AstraZeneca to be its CEO - has entered a clinical collaboration with Genentech Inc. to evaluate the safety, tolerability and preliminary efficacy of its lead asset, entinostat, an oral small molecule targeting immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with the Roche Holding AG biologics division's PD-L1 inhibitor atezolizumab in patients with triple-negative breast cancer.
You may also be interested in...
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.